Target intelligence / Profile preview

Ret proto-oncogene receptor tyrosine kinase (RET) (RET)

Target
RET
Molecular classification
Receptor, Receptor tyrosine kinase (RTK), Enzyme (protein kinase)
01

Overview

RET is a membrane-spanning receptor tyrosine kinase with a large extracellular domain containing four cadherin-like repeats and a cysteine-rich region, a single-pass transmembrane segment, and an intracellular tyrosine kinase domain. Activation requires binding of glial cell line-derived neurotrophic factor (GDNF) family ligands to GFRα co-receptors, which recruit and dimerize RET in lipid rafts, leading to kinase activation and autophosphorylation. Phosphorylated tyrosines (notably Tyr1062; Tyr1096 in RET51) serve as docking sites to propagate signaling through MAPK/ERK, PI3K/AKT, PLCγ, and other pathways controlling growth, survival, and differentiation. Alternative splicing produces major isoforms RET9 and RET51 with distinct C-termini and signaling features. Germline activating mutations drive MEN2A/2B, while somatic RET fusions act as oncogenic drivers in several cancers; conversely, loss-of-function mutations cause Hirschsprung’s disease.

Other names
Rearranged during transfection (RET)Proto-oncogene protein c-RETRET proto-oncogene receptor tyrosine kinase
02

Mechanism of action

ATP-competitive inhibition of the RET intracellular tyrosine kinase domain, blocking autophosphorylation and downstream signaling (e.g., MAPK and PI3K/AKT)

03

Biological functions

Signal transduction via MAPK/ERK, PI3K/AKT, STAT3, Src, and focal adhesion kinase pathwaysNeural crest, kidney/urogenital, and enteric nervous system developmentCell proliferation, survival, and differentiation
04

Disease associations

Cancer (papillary thyroid carcinoma via RET fusions; multiple endocrine neoplasia type 2A/2B; pheochromocytoma; parathyroid hyperplasia)Developmental disorders (Hirschsprung’s disease from loss-of-function mutations)
05

Safety considerations

On-target kinase inhibition in normal RET-expressing tissues can affect development/neuronal signaling; resistance mutations and bypass signaling are recognized therapeutic challenges in RET-targeted therapy
06

Interacting drugs

Selective RET inhibitors: selpercatinib, pralsetinib (examples; class targets RET kinase)

1 more in the full profile.

07

Biomarkers

RET gene fusions (e.g., in papillary thyroid carcinoma and other tumors) for predicting sensitivity to RET inhibitorsRET activating point mutations (e.g., MEN2-associated) for selecting targeted therapy

Beyond the preview

Go deeper on Ret proto-oncogene receptor tyrosine kinase (RET) (RET).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ret proto-oncogene receptor tyrosine kinase (RET) (RET).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call